Lupin Healthcare (UK)
-
Lupin’s UK subsidoary receives marketing authorisation for Luforbec
Luforbec 100/6 µg pMDI is indicated for regular treatment of asthma and the symptomatic treatment of patients with severe COPD…
Read More »
Luforbec 100/6 µg pMDI is indicated for regular treatment of asthma and the symptomatic treatment of patients with severe COPD…
Read More »